GlassScriptPhysician profile
Jean P Cole
NPI 1962451807
$3,423.93
in general payments reported to CMS, 2019-2025
31 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $503 · 2021: $802 · 2022: $610 · 2023: $594 · 2024: $254 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,112.90 | 2019-2023 | |
| Exeltis, USA INC. | $386.11 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $211.29 | 2022-2023 | |
| Myriad Women'S Health, INC. | $165.56 | 2023 | Myrisk |
| Therapeuticsmd, INC. | $160.14 | 2019-2021 | |
| Myovant Sciences INC. | $152.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $115.52 | 2019-2024 | Gardasil 9, Gardasil |
| Lupin INC. | $108.47 | 2019-2021 | |
| Baxter Healthcare | $94.77 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $93.94 | 2023-2025 | Myfembree, Gemtesa |
| Organon LLC | $87.67 | 2022-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $83.99 | 2019-2023 | Myosure Tissue Removal Device |
| Astellas Pharma US INC | $82.53 | 2023-2025 | Veozah |
| Amag Pharmaceuticals, INC. | $79.35 | 2019 | |
| Evofem Biosciences, INC. | $76.80 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $58.82 | 2023 | Stravix Pl |
| Davol INC. | $44.69 | 2021-2025 | Arista |
| Shield Therapeutics INC | $34.27 | 2023 | Accrufer |
| Millicent US INC | $33.34 | 2020-2024 | Intrarosa |
| Zyla Life Sciences, INC. | $29.05 | 2020 | |
| Allergan, INC. | $28.76 | 2019-2020 | |
| Avion Pharmaceuticals | $25.88 | 2020-2021 | |
| Ethicon US, LLC | $22.93 | 2019 | |
| Roche Diagnostics Corporation | $19.87 | 2019 | |
| Becton, Dickinson and Company | $19.34 | 2024 | Arista Ah Flexitip |
| Convatec INC. | $17.82 | 2024 | |
| Dysis Medical, INC. | $17.39 | 2021 | |
| Covidien LP | $16.62 | 2019 | |
| Coopersurgical, INC. | $16.08 | 2024 | Paragard T 380a |
| Aesculap, INC. | $15.50 | 2019 | |
| Novo Nordisk INC | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.